CN104126801B - A kind of blood-fat reducing composition containing sterol - Google Patents
A kind of blood-fat reducing composition containing sterol Download PDFInfo
- Publication number
- CN104126801B CN104126801B CN201410394353.4A CN201410394353A CN104126801B CN 104126801 B CN104126801 B CN 104126801B CN 201410394353 A CN201410394353 A CN 201410394353A CN 104126801 B CN104126801 B CN 104126801B
- Authority
- CN
- China
- Prior art keywords
- tea polyphenols
- blood
- food
- phytosterol
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of blood-fat reducing composition containing sterol, formed by following component by quality: phytosterol 24%～35%, red colouring agent for food, also used as a Chinese medicine 17%～28%, Tea Polyphenols 3%～8%, lactose 18%～30%, dextrin 7%～12%, sodium carboxymethyl starch 5%～8%, dolomol 0.7%～1%; The purity of described phytosterol is >=90%, and the Lovastatin quality in red colouring agent for food, also used as a Chinese medicine accounts for described composition >=0.08%, and the Tea Polyphenols quality in Tea Polyphenols accounts for described composition >=3%. Its main component phytosterol of composition of the present invention, red colouring agent for food, also used as a Chinese medicine and Tea Polyphenols three compatibility play synergy, can suppress the absorption of cholesterol and triglycerides and synthesize, accelerate metabolism and the excretion of cholesterol and triglycerides, effectively reduce TC, TG, LDL-C level in blood, HDL-C level in rising blood, reaches effect of significant reduction blood fat.
Description
Technical field
The present invention relates to a kind of blood-fat reducing composition containing sterol.
Background technology
In modern medicine, hyperlipidemia be due to fat metabolism or running extremely make cholesterol (TC), triglycerides (TG) and (or)A kind of illness that low-density lipoprotein (LDL) is too high and (or) HDL (HDL) is too low and cause. Dyslipidemia is embodied inThe change of one or several index content such as TC, TG and LDL, HDL etc. To detect clinically blood fat project as the interior blood that disintegratesAn important means of fat metabolism status, lipids detection project mainly contains TC, TG, and apolipoprotein is serial as HDL, LDL etc.,These projects are synthetic, the metabolism situation of blood fat in ipsilateral antimer never, and clinical diagnosis, treatment and research are all had shouldBy value. Along with improving constantly of people's living standard, the incidence of disease of hyperlipidemia is obvious ascendant trend. Therefore find efficientNontoxic blood lipid-lowering medicine and health medicine have important realistic meaning.
The present invention relates to a kind of whole formula of blood-fat reducing composition containing sterol is mainly according to modern medical theory prescription, with plantSterol, red colouring agent for food, also used as a Chinese medicine, Tea Polyphenols are primary raw material. Phytosterol is that to utilize soybean wet goods vegetable oil cut or Tall oil be raw material,Making by explained hereafter such as saponification, extraction, crystallizations, is a kind of natural active matter being present in plant. Phytosterol canHinder competitively intestinal absorption cholesterol, promote that cholesterol excretes, can significantly reduce serum TC, LDL-C level, reachTo the effect of reducing blood lipid. Red colouring agent for food, also used as a Chinese medicine is taking rice as raw material, breeds a kind of aubergine rice song forming through monascus, and its taste is sweet, propertyTemperature, returns liver, spleen, large intestine channel, have promoting blood circulation and removing blood stasis, effect of reinforcing spleen to promote digestion, its active ingredient contestable suppresses cholesterolAn important rate-limiting enzyme in anabolism, thus the synthetic of cholesterol reduced, can effectively reduce TC, TG, LDL-C water in bloodFlat, HDL-C level in rising blood, effectively reduces blood fat. Tea Polyphenols is the class polyphenol chemical combination extracting from natural plants tealeavesThing complex, accounts for greatly 25% of dry weight of tea leaves, mainly comprises catechin, flavones and flavonols, flower by its chemical constitutionThe four large class materials such as pigment, phenolic acid and depside. Tea Polyphenols has plurality of health care functions and pharmacodynamics effect, and it can suppress intestinesThe absorption of exogenous cholesterol in road, accelerates the metabolism of cholesterol and the excretion of promotion cholesterol, can reduce the suction of exogenous TGThe metabolism of TG and the excretion of promotion aliphatic acid received, accelerated, thereby TC, TG metabolism regulated. Experiment showed, that Tea Polyphenols can reduceThe level of TG, TC and LDL-C in serum, rising HDL-C level. The mutual compatibility of three, synergy, can suppress cholesterolAnd the absorption of triglycerides and synthetic, accelerate metabolism and the excretion of cholesterol and triglycerides, effectively reduce TC in blood, TG, LDL-CLevel, HDL-C level in rising blood, reaches the effect that reduces blood fat.
Summary of the invention
The object of this invention is to provide blood-fat reducing composition a kind of determined curative effect, that contain efficiently sterol.
Technical scheme of the present invention is summarized as follows:
Containing the blood-fat reducing composition of sterol, formed by following component by quality: phytosterol 24%～35%, red colouring agent for food, also used as a Chinese medicine 17%～28%, Tea Polyphenols 3%～8%, lactose 18%～30%, dextrin 7%～12%, sodium carboxymethyl starch 5%～8%, dolomol 0.7%～1%; Purity >=90% of described phytosterol, the Lovastatin quality in red colouring agent for food, also used as a Chinese medicine accounts for described composition >=0.08%, in Tea PolyphenolsTea Polyphenols quality account for described composition >=3%.
Composition of the present invention can method routinely be made oral formulations, comprising: granule, tablet or pulvis etc.
Its main component phytosterol of composition of the present invention, red colouring agent for food, also used as a Chinese medicine and Tea Polyphenols three compatibility play synergy, can suppress courage solidThe absorption of alcohol and triglycerides and synthetic, accelerates metabolism and the excretion of cholesterol and triglycerides, effectively reduce TC in blood, TG,LDL-C level, HDL-C level in rising blood, reaches effect of significant reduction blood fat.
Detailed description of the invention
The following examples are in order to enable those skilled in the art to understand better the present invention, but the present invention are not appointedWhat restriction.
Phytosterol used in the present invention, its standard is Q/17A0772S-2011, sky section of China Oil and Food Import and Export Corporation bioengineering (Tianjin) hasLimit company sells, and the phytosterol that meets other enterprise of above-mentioned standard also can be for the present invention.
Tea Polyphenols: product standard " QB2154-1995 food additives Tea Polyphenols ", light industry professional standard.
Embodiment 1
Containing the blood-fat reducing composition of sterol, made by following component by weight percentage: phytosterol 28%, red colouring agent for food, also used as a Chinese medicine 22%,Tea Polyphenols 6%, lactose 28%, dextrin 8%, sodium carboxymethyl starch 7%, dolomol 1%; Wherein the purity of phytosterol is 90%,Lovastatin quality in red colouring agent for food, also used as a Chinese medicine accounts for 0.08% of described composition, and the Tea Polyphenols quality in Tea Polyphenols accounts for described composition 3%.
Embodiment 2
Containing the blood-fat reducing composition of sterol, made by following component by weight percentage: phytosterol 24%, red colouring agent for food, also used as a Chinese medicine 28%,Tea Polyphenols 8%, lactose 19.3%, dextrin 12%, sodium carboxymethyl starch 8%, dolomol 0.7%; The wherein purity of phytosterolBe 90.5%, the Lovastatin quality in red colouring agent for food, also used as a Chinese medicine accounts for 0.083% of described composition, and the Tea Polyphenols quality in Tea Polyphenols accounts for described groupCompound 3.1%.
Embodiment 3
Containing the blood-fat reducing composition of sterol, made by following component by weight percentage: phytosterol 29%, red colouring agent for food, also used as a Chinese medicine 17%,Tea Polyphenols 8%, lactose 30%, dextrin 7%, sodium carboxymethyl starch 8%, dolomol 1%; Wherein the purity of phytosterol is 90.5%,Lovastatin quality in red colouring agent for food, also used as a Chinese medicine accounts for 0.083% of described composition, and the Tea Polyphenols quality in Tea Polyphenols accounts for described composition 3.1%.
Embodiment 4
Containing the blood-fat reducing composition of sterol, made by following component by weight percentage: phytosterol 35%, red colouring agent for food, also used as a Chinese medicine 18%,Tea Polyphenols 3%, lactose 30%, dextrin 8%, sodium carboxymethyl starch 5%, dolomol 1%; Wherein the purity of phytosterol is 90.5%,Lovastatin quality in red colouring agent for food, also used as a Chinese medicine accounts for 0.083% of described composition, and the Tea Polyphenols quality in Tea Polyphenols accounts for described composition 3.1%.
Embodiment 5
Containing the blood-fat reducing composition of sterol, made by following component by weight percentage: phytosterol 30%, red colouring agent for food, also used as a Chinese medicine 27%,Tea Polyphenols 6%, lactose 18%, dextrin 10%, sodium carboxymethyl starch 8%, dolomol 1%; Wherein the purity of phytosterol is 90.5%,Lovastatin quality in red colouring agent for food, also used as a Chinese medicine accounts for 0.083% of described composition, and the Tea Polyphenols quality in Tea Polyphenols accounts for described composition 3.1%.
Embodiment 6
Preparation method:
1) sieve: by phytosterol, red colouring agent for food, also used as a Chinese medicine, Tea Polyphenols, lactose, dextrin, sodium carboxymethyl starch, dolomol mistake respectively80 mesh sieves, each component takes by each Example formulations amount respectively, for subsequent use;
2) mix: phytosterol, red colouring agent for food, also used as a Chinese medicine, Tea Polyphenols, lactose, dextrin and sodium carboxymethyl starch are put in mixer and mixed 30Minute, mix, obtain total mixed powder;
3) granulate: be 50% ethanol water to adding appropriate volumetric concentration in total mixed powder, stir, softwood processed;Cross 18 mesh sieves with oscillating granulator again and granulate, obtain wet granular. Wet granular is with HighefficientFluidbeddrier dry (approximately 50 DEG C), dryThe whole grain of dry rear mistake 18 orders, obtains dry particle;
4) compressing tablet: dry particle and dolomol are put in mixer and mixed 5 minutes, mix, obtain always mixed particle; Total mixedGrain use high speed tablet press compressing tablet, trimmer is heavily 1.0g/ sheet, rejects defective, obtains plain sheet;
5) dressing: take coating powder, adding volumetric concentration is 70% ethanol water, stirs, and makes quality denseDegree is 8% coating powder solution. Sugar coating machine dressing for the sheet heart (increasing weight approximately 2%), obtains coating tablet.
Can also be prepared into according to a conventional method granule or pulvis etc.
Embodiment 7
The present invention is containing auxiliary lipid-lowering function zoopery (foundation " the health food inspection and evaluation skill of the blood-fat reducing composition of sterolArt specification (2003 editions) " content tests).
Auxiliary lipid-lowering function zoopery
1 materials and methods
1.1 samples: press step 4 in the composition of embodiment 1 and the preparation method of embodiment 6) (the abbreviation lipopenicillinase of the rear plain sheet obtainingSheet).
1.2 animals used as test: select body weight 152～175g, 40 of SPF level male Wistar rats, by Beijing, dimension tonneau China is realTesting animal Science and Technology Ltd. provides, the quality certification number: SCXK (capital) 2006-00090191366.
1.3 animal used as test high lipid foods: feed is provided by the feed corporation,Ltd that pulls together of Beijing Australia of section, the feed quality certification number: SCXK (capital)2009-00120193842, filling a prescription is: basal feed 78.8%, cholesterol 1%, lard 10%, yolk powder 10%, 0.2%Cholate.
1.4 experimental animal feeding environment: SPF level experimental animal room, 20～25 DEG C of temperature, relative humidity 40～70%RH is qualifiedCard number: SYXK (Tianjin) 2008-0004.
1.5 dosage groupings: tablets of reducing blood fat, people intend with dosage be 6.0g/60kgBW day, specifically dosage is designed to: 0.5g/kgBW,1.0g/kgBW, 2.0g/kgBW, be equivalent to respectively people and intend 5 times, 10 times, 20 times with dosage. Take respectivelyTested material 20.0g, 40.0g, 80.0g, each adding distil water is to 400ml, and per os gavage, all vibrates and mixes before each gavage,Gavage amount 1.0ml/100gBW, model control group gives equivalent distilled water, every day 1 time, carries out continuously 30 days. AnimalSingle cage is fed.
1.6 experimental techniques: employing hyperlipoidemia method-preventative given the test agent of giving, under experimental situation, feed with basal feedRaise rat and observe after 5 days, angular vein clump is got blood, enzymatic assays serum total cholesterol (TC), triglycerides (TG) andHDL-C (HDL-C), is divided into 4 groups according to TC level at random by animal: model control group and 3 are subject toExamination thing group, every group of 10 animals, from formal experiment, each treated animal is fed and is raised high lipid food, except model control group,Per os gavage gives the tested material of various dose simultaneously. Experiment finishes rear fasting 16h, and angular vein clump is got blood, measures serumTC, TG and HDL-C.
1.7 key instruments and reagent: TOSHIBATBA-40FR automatic clinical chemistry analyzer. T-CHOL (TC), triglycerides(TG) and HDL-C (HDL-C) kit, carry by Beijing Zhong Shengbei control Bioisystech Co., LtdSupply.
1.8 statistical methods: respectively organize data and all adopt variance analysis in SPSS11.5FORWINDOWS to carry out statistical analysis, variance is notNeat person adopts data transaction, adopts nonparametric statistics as still uneven after conversion.
2 results
The impact of 2.1 tablets of reducing blood fat on rat body weight
From table 1, with the tablets of reducing blood fat gavage rat of various dose 30 days, each treated animal growth, movable normal. Each doseThe weightening finish of amount treated animal and model control group comparison, the equal not statistically significant of difference (P > 0.05).
The impact (g, means standard deviation) of table 1 tablets of reducing blood fat on rat body weight
Experiment showed, embodiment 2-5 the preparation method of composition embodiment 6 in the plain sheet that the obtains impact on rat body weightThe result of result and embodiment 1 is approximate.
The impact of 2.2 tablets of reducing blood fat on rat fat
From table 2～4, test latter stage, high dose group animal blood serum T-CHOL (TC) and triglyceride (TG) are equalLower than model control group, high dose group HDL (HDL-C) is higher than model control group, and difference has statistics meaningJustice (P<0.05); All the other each dosage groups, indices and model control group comparison, difference not statistically significant (P>0.05).
The impact (means standard deviation) of table 2 tablets of reducing blood fat on Serum TC
* with control group comparison, difference has statistical significance (P < 0.05)
The impact (means standard deviation) of table 3 tablets of reducing blood fat on rat blood serum TG
* with control group comparison, difference has statistical significance (P < 0.05)
The impact (means standard deviation) of table 4 tablets of reducing blood fat on rat blood serum HDL-C
* with control group comparison, difference has statistical significance (P < 0.05)
Experiment showed, embodiment 2-5 the preparation method of composition embodiment 6 in the impact of the plain sheet rat fat that obtainsResult and the result of embodiment 1 approximate.
3 brief summaries
With 0.5g/kgBW, 1.0g/kgBW, 2.0g/kgBW dosage (be equivalent to respectively people intend with 5 times of dosage,10 times, 20 times) tablets of reducing blood fat gavage rat 30 days, each treated animal vegetative activity is good, each dosage treated animal weightening finish and mouldType control group is compared, difference not statistically significant (P > 0.05); High dose group animal blood serum T-CHOL (TC) and glycerineThree esters (TG) are all lower than model control group, and difference has statistical significance (P < 0.05); High dose group HDL(HDL-C) higher than model control group, and difference has statistical significance (P < 0.05). According to " health food is checked and commentedValency technical specification " (version in 2003) auxiliary lipid-lowering function result criterion, prompting tablets of reducing blood fat has the auxiliary animal that reducesBlood fat function.
Claims (1)
1. containing the blood-fat reducing composition of sterol, it is characterized in that the following method of described composition makes:
1) sieve: by phytosterol, red colouring agent for food, also used as a Chinese medicine, Tea Polyphenols, lactose, dextrin, sodium carboxymethyl starch, dolomol mistake respectively80 mesh sieves, each component takes by quality respectively: phytosterol 24%～35%, red colouring agent for food, also used as a Chinese medicine 17%～28%, Tea Polyphenols 3%～8%, breastSugar 18%～30%, dextrin 7%～12%, sodium carboxymethyl starch 5%～8%, dolomol 0.7%～1%; Described phytosterol pureDegree is for >=90%, and the Lovastatin quality in red colouring agent for food, also used as a Chinese medicine accounts for described composition >=0.08%, and the Tea Polyphenols quality in Tea Polyphenols accounts for described groupCompound >=3%; For subsequent use;
2) mix: phytosterol, red colouring agent for food, also used as a Chinese medicine, Tea Polyphenols, lactose, dextrin and sodium carboxymethyl starch are put in mixer and mixed 30Minute, mix, obtain total mixed powder;
3) granulate: be 50% ethanol water to adding volumetric concentration in total mixed powder, stir, softwood processed; Again with shakingPendulum-type granulator is crossed 18 mesh sieves and is granulated, and obtains wet granular; Wet granular is dry with 50 DEG C of HighefficientFluidbeddriers, dry rear 18 orders of crossingWhole grain, obtains dry particle;
4) compressing tablet: dry particle and dolomol are put in mixer and mixed 5 minutes, mix, obtain always mixed particle; Total mixedGrain use high speed tablet press compressing tablet, trimmer is heavily 1.0g/ sheet, rejects defective, obtains plain sheet;
5) dressing: take coating powder, adding volumetric concentration is 70% ethanol water, stirs, and makes quality denseDegree is 8% coating powder solution; Element sheet sheet heart sugar coating machine dressing, obtains coating tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410394353.4A CN104126801B (en) | 2014-08-12 | 2014-08-12 | A kind of blood-fat reducing composition containing sterol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410394353.4A CN104126801B (en) | 2014-08-12 | 2014-08-12 | A kind of blood-fat reducing composition containing sterol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104126801A CN104126801A (en) | 2014-11-05 |
| CN104126801B true CN104126801B (en) | 2016-05-18 |
Family
ID=51799851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410394353.4A Active CN104126801B (en) | 2014-08-12 | 2014-08-12 | A kind of blood-fat reducing composition containing sterol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104126801B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105124569A (en) * | 2015-07-13 | 2015-12-09 | 北京世纪合辉医药科技股份有限公司 | Blood-fat-reducing health-caring food and preparation method of same |
| CN105494812A (en) * | 2015-12-29 | 2016-04-20 | 中粮集团有限公司 | Beverage capable of lowering blood lipid and application of beverage |
| CN105535601A (en) * | 2015-12-30 | 2016-05-04 | 徐州市铜山区生命科学研究院 | Medicinal and edible dual-purpose compound red yeast rice phytosterol health protection medicine for preventing and treating cardio-cerebrovascular disease and preparation method thereof |
| CN105533747A (en) * | 2015-12-31 | 2016-05-04 | 哈药集团技术中心 | Health food capable of assisting in reduction of blood fat |
| CN106620344A (en) * | 2016-12-27 | 2017-05-10 | 南京圣诺生物科技实业有限公司 | Composition with blood lipid lowering effect and preparation method thereof |
| CN109596844A (en) * | 2018-12-18 | 2019-04-09 | 江苏大学附属医院 | It is a kind of to detect the drug and application that metabolic syndrome is fallen ill |
| CN109619571A (en) * | 2019-02-20 | 2019-04-16 | 吉林大学 | A kind of panax ginseng plant sterol chewable tablets and preparation method thereof with hypolipemic function |
| CN113730547A (en) * | 2021-09-17 | 2021-12-03 | 江苏协合转化医学研究院有限公司 | Composition for reducing blood fat and dissolving thrombus, preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1539475A (en) * | 2003-10-27 | 2004-10-27 | 张文高 | Combination of natural products for curing hyperlipemia, atherosclerosis and relevant disease |
| CN101496581A (en) * | 2008-02-03 | 2009-08-05 | 于珩 | Health-care food for adjusting blood fat |
| CN102205010A (en) * | 2011-05-25 | 2011-10-05 | 遵义陆圣康源科技开发有限责任公司 | Pharmaceutical composition with auxiliary function of reducing blood fat |
| CN103766902A (en) * | 2014-01-10 | 2014-05-07 | 杭州海王生物工程有限公司 | Powder with effect of helping to lower blood lipid and preparation method of powder |
-
2014
- 2014-08-12 CN CN201410394353.4A patent/CN104126801B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1539475A (en) * | 2003-10-27 | 2004-10-27 | 张文高 | Combination of natural products for curing hyperlipemia, atherosclerosis and relevant disease |
| CN101496581A (en) * | 2008-02-03 | 2009-08-05 | 于珩 | Health-care food for adjusting blood fat |
| CN102205010A (en) * | 2011-05-25 | 2011-10-05 | 遵义陆圣康源科技开发有限责任公司 | Pharmaceutical composition with auxiliary function of reducing blood fat |
| CN103766902A (en) * | 2014-01-10 | 2014-05-07 | 杭州海王生物工程有限公司 | Powder with effect of helping to lower blood lipid and preparation method of powder |
Non-Patent Citations (2)
| Title |
|---|
| 复方植物甾醇片工艺研究;李健等;《哈尔滨商业大学学报》;20131230;第29卷(第6期);第667-670页 * |
| 红曲_植物甾醇酯复方制剂调血脂作用研究;赵珺彦;《中草药》;20111130;第42卷(第11期);第2296-2299页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104126801A (en) | 2014-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104126801B (en) | A kind of blood-fat reducing composition containing sterol | |
| CN103385315B (en) | Vegetable oil composition with hypolipidemic effect as well as preparation method and application thereof | |
| CN1243559C (en) | Herbal composition and medicament against diabetes mellitus type II manufactured thereof | |
| CN111494495A (en) | Application of litchi pulp dietary fiber-bonded phenol adduct in preparation of preparation for improving intestinal microecology | |
| CN106214773B (en) | A kind of pair of chemical damage has composition of assistant protection function and preparation method thereof | |
| CN102283876B (en) | Method for producing ternary tablets by using bee products and American ginseng as main materials | |
| CN103960587B (en) | A kind of preparation technology of acorn nut healthy fine dried noodles | |
| CN104957423A (en) | Health-care fodder for bamboo rats and preparation method thereof | |
| CN107319553A (en) | A kind of health products of auxiliary hyperglycemic strengthen immunity and preparation method thereof | |
| CN106617072A (en) | Phytosterol compound lipid-decreasing formula and preparation method for tablet thereof | |
| EP3275457A1 (en) | Pharmaceutical composition containing silybin | |
| CN101234160B (en) | Fat-reducing and liver-protecting Chinese medicine preparation and preparation thereof | |
| CN104366054A (en) | Feed of rabbit suitable for diabetics to eat | |
| CN110882359A (en) | Naqu preparation and preparation method thereof | |
| CN103830280B (en) | Preparation method of spirulina extract | |
| WO2021174801A1 (en) | Method for preparing antrodia cinnamomea water-insoluble dietary fibers | |
| CN105147899A (en) | Preparation for protecting stomach, protecting liver and dissipating effects of alcohol and application of preparation | |
| US20140377388A1 (en) | Cholesterol discharge-accelerating agent and neutral fat discharge-accelerating agent using sunflower pith | |
| CN108771248A (en) | A kind of health-care food for assisting blood fat lowering full of nutrition and preparation method thereof | |
| CN106605920A (en) | Mangosteen enzyme nutrition liquid and preparation method thereof | |
| Zhang et al. | Effects of liposoluble components of highland barley spent grains on physiological indexes, intestinal microorganisms, and the liver transcriptome in mice fed a high‐fat diet | |
| CN103750317B (en) | Andrias davidianus oil sustained-release dropping pill | |
| CN105232802B (en) | Procyanidine composition with blood fat reducing effect and preparation method and application thereof | |
| CN103892041A (en) | Duckling feed and preparation method thereof | |
| CN107411085A (en) | It is a kind of to adjust health-care food composition of blood fat and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Cao Yuping Inventor after: Zhou Xuejin Inventor after: Chen Lishui Inventor after: Xu Yongan Inventor after: Yang Wei Inventor after: Wu Wenhua Inventor after: Liang Guangzhen Inventor after: Jiang Yiming Inventor after: Chen Xuebing Inventor before: Zhou Xuejin Inventor before: Cao Yuping Inventor before: Jiang Yiming Inventor before: Chen Xuebing Inventor before: An Ran |
|
| COR | Change of bibliographic data | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |